Home›The Library›Trofinetide
Trofinetide
Trofinetide (Daybue) is a real, FDA-approved synthetic analog of a natural IGF-1 breakdown fragment — the first and, so far, only approved treatment for Rett syndrome, a severe genetic neurodevelopmental disorder.
On this page
In brief
Should you care? Relevant if you or someone you know has Rett syndrome — the first FDA-approved treatment specifically for it, with a modest but real, statistically significant effect.The short version
- A synthetic tripeptide analog of glycine-proline-glutamate (GPE), a fragment naturally produced when IGF-1 is broken down in the brain.
- Approved March 2023 as the first drug specifically for Rett syndrome, based on the LAVENDER trial.
- A modest, not dramatic, effect — the trial met its endpoints with real but limited score improvements, and gastrointestinal side effects are common enough to affect adherence.
A synthetic analog of a natural IGF-1 fragment
Trofinetide is a synthetic analog of glycine-proline-glutamate (GPE), a small tripeptide naturally cleaved from IGF-1 in the brain and thought to carry some of IGF-1's neuroprotective signaling separately from its growth-promoting effects. Rett syndrome is caused by mutations in the MECP2 gene and severely disrupts brain development, almost always in girls; trofinetide does not correct the underlying genetic defect but is intended to modulate the resulting neuroinflammation and synaptic dysfunction.
The approval and pivotal trial
The FDA approved trofinetide (as Daybue) on 10 March 2023 for Rett syndrome in adults and children two years of age and older — the first drug ever approved specifically for this condition. Approval rested on the Phase 3 LAVENDER trial (Neul et al., Nat Med 2023;29(6):1468-1475, PMID 37291210), 187 female patients aged 5-20 with Rett syndrome, randomized to trofinetide or placebo for 12 weeks. The trial met both co-primary endpoints: change from baseline in the Rett Syndrome Behaviour Questionnaire (RSBQ) total score (p=0.018) and the Clinical Global Impression-Improvement (CGI-I) scale (p=0.003), both favoring trofinetide.
Safety
No boxed warning, but diarrhea and vomiting were the most common adverse reactions in the pivotal trial, common enough that some patients discontinued treatment because of them; the label recommends starting at a lower dose and titrating up partly to manage this. There is no evidence trofinetide affects the underlying MECP2 genetic defect or reverses the disorder's developmental course — its measured benefit is a statistically significant but incremental improvement in specific behavioral and clinical-impression scores, not a cure.
Current status
Marketed by Acadia Pharmaceuticals as Daybue, available as an oral solution and, more recently, an oral powder ("Daybue Stix") formulation intended to improve palatability and adherence. No generic version exists.
References
- Neul JL, Percy AK, Benke TA, et al., "Trofinetide for the Treatment of Rett Syndrome: A Randomized Phase 3 Study," Nat Med 2023;29(6):1468-1475, PMID 37291210.
- FDA approval history for Daybue (trofinetide), 10 March 2023.